ArticlePloS one2015
Blinded Validation of Breath Biomarkers of Lung Cancer, a Potential Ancillary to Chest CT Screening.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00639067 (Breath Test Assay for the Adjunctive Detection of Lung Cancer), which is not on this map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Breath Test Assay for the Adjunctive Detection of Lung Cancer
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Breath based volatile organic compounds in the detection of breast, lung, and colorectal cancers: A systematic review.Cancer biomarkers : section A of Disease markers · 2017Pooled it
- Collection methods of exhaled volatile organic compounds for lung cancer screening and diagnosis: a systematic review.Journal of thoracic disease · 2024Review
- The human volatilome meets cancer diagnostics: past, present, and future of noninvasive applications.Metabolomics : Official journal of the Metabolomic Society · 2024Review
- Diagnosis of Carcinogenic Pathologies through Breath Biomarkers: Present and Future Trends.Biomedicines · 2023Review
- Review
- Breath Biomarkers of Influenza Infection.Open forum infectious diseases · 2022Article
- The promises and challenges of early non-small cell lung cancer detection: patient perceptions, low-dose CT screening, bronchoscopy and biomarkers.Molecular oncology · 2021Review
- Micro-Chamber/Thermal Extractor (µ-CTE) as a new sampling system for VOCs emitted by feces.Scientific reports · 2021Article
- Clinical Utility of microRNAs in Exhaled Breath Condensate as Biomarkers for Lung Cancer.Journal of personalized medicine · 2021Article
- Mass Spectrometry-based Metabolomics in Translational Research.Advances in experimental medicine and biology · 2021Review
- Volatile Organic Compounds in Exhaled Breath as Fingerprints of Lung Cancer, Asthma and COPD.Journal of clinical medicine · 2020Review
- Focal organizing pneumonia in patients: differentiation from solitary bronchioloalveolar carcinoma using dual-energy spectral computed tomography.American journal of translational research · 2020Article
- Whole blood FPR1 mRNA expression predicts both non-small cell and small cell lung cancer.International journal of cancer · 2018Article
- Progress and prospects of early detection in lung cancer.Open biology · 2017Review
- Exhaled breath analysis for the early detection of lung cancer: recent developments and future prospects.Lung Cancer (Auckland, N.Z.) · 2017Review
- Normalization of Exhaled Carbonyl Compounds After Lung Cancer Resection.The Annals of thoracic surgery · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 1 country.
Funding
Abstract
backgroundBreath volatile organic compounds (VOCs) have been reported as biomarkers of lung cancer, but it is not known if biomarkers identified in one group can identify disease in a separate independent cohort. Also, it is not known if combining breath biomarkers with chest CT has the potential to improve the sensitivity and specificity of lung cancer screening.
methodsModel-building phase (unblinded): Breath VOCs were analyzed with gas chromatography mass spectrometry in 82 asymptomatic smokers having screening chest CT, 84 symptomatic high-risk subjects with a tissue diagnosis, 100 without a tissue diagnosis, and 35 healthy subjects. Multiple Monte Carlo simulations identified breath VOC mass ions with greater than random diagnostic accuracy for lung cancer, and these were combined in a multivariate predictive algorithm. Model-testing phase (blinded validation): We analyzed breath VOCs in an independent cohort of similar subjects (n = 70, 51, 75 and 19 respectively). The algorithm predicted discriminant function (DF) values in blinded replicate breath VOC samples analyzed independently at two laboratories (A and B). Outcome modeling: We modeled the expected effects of combining breath biomarkers with chest CT on the sensitivity and specificity of lung cancer screening.
resultsUnblinded model-building phase. The algorithm identified lung cancer with sensitivity 74.0%, specificity 70.7% and C-statistic 0.78. Blinded model-testing phase: The algorithm identified lung cancer at Laboratory A with sensitivity 68.0%, specificity 68.4%, C-statistic 0.71; and at Laboratory B with sensitivity 70.1%, specificity 68.0%, C-statistic 0.70, with linear correlation between replicates (r = 0.88). In a projected outcome model, breath biomarkers increased the sensitivity, specificity, and positive and negative predictive values of chest CT for lung cancer when the tests were combined in series or parallel.
conclusionsBreath VOC mass ion biomarkers identified lung cancer in a separate independent cohort, in a blinded replicated study. Combining breath biomarkers with chest CT could potentially improve the sensitivity and specificity of lung cancer screening.
trial registrationClinicalTrials.gov NCT00639067.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.